ANTI-ETANERCEPT ANTIBODIES AND ETANERCEPT LEVES LEVELS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH LOW AND FULL-DOSE ETANERCEPT IN DAS28 REMISSION

被引：0
|
作者：
Ometto, F. [1 ]
Beggio, M. [1 ]
Friso, L. [1 ]
Astorri, D. [1 ]
Raffeiner, B. [1 ,2 ]
Botsios, C. [1 ]
Bernardi, L. [1 ]
Padoan, R. [1 ]
Punzi, L. [1 ]
机构：
[1] Univ Padua, Med Dept DIMED, Rheumatol Unit, Padua, Italy
[2] Gen Hosp Bolzano, Internal Med, Rheumatol Unit, Bolzano, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.5841
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0178
引用
收藏
页码：494 / 494
页数：1
相关论文
共 50 条
  • [41] Comparison Of Effects Of Standard- and Low-Dose Etanercept On Inflammatory Synovitis In Rheumatoid Arthritis Patients As Assessed By Ultrasonography
    Mamoto, Kenji
    Koike, Tatsuya
    Okano, Tadashi
    Sugioka, Yuko
    Tada, Masahiro
    Inui, Kentaro
    Nakamura, Hiroaki
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S615 - S615
  • [42] Nucleosome accumulation and reduction of C-reactive protein are associated with the generation of anti-nuclear antibodies in patients with rheumatoid arthritis treated with adalimumab, but not with etanercept
    Priori, R.
    Alessandri, C.
    Magrini, L.
    Cassara, E. A. M.
    Ceccarelli, F.
    Modesti, M.
    Croia, C.
    Bombardieri, M.
    Valesini, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (09) : 1514 - 1516
  • [43] Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting
    Maid, Pablo J.
    Xavier, Ricardo
    Real, Rosa M.
    Pedersen, Ron
    Shen, Qi
    Marshall, Lisa
    Solano, Gaston
    Elena Borlenghi, Cecilia
    Pardo Hidalgo, Rodolfo
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 (04) : 177 - 182
  • [44] Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
    Shinya Hirabara
    Nobunori Takahashi
    Naoki Fukaya
    Hiroyuki Miyake
    Yuichiro Yabe
    Atsushi Kaneko
    Takayasu Ito
    Takeshi Oguchi
    Daihei Kida
    Yuji Hirano
    Takayoshi Fujibayashi
    Fumiaki Sugiura
    Masatoshi Hayashi
    Koji Funahashi
    Masahiro Hanabayashi
    Shuji Asai
    Naoki Ishiguro
    Toshihisa Kojima
    Clinical Rheumatology, 2014, 33 : 1247 - 1254
  • [45] Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
    Hirabara, Shinya
    Takahashi, Nobunori
    Fukaya, Naoki
    Miyake, Hiroyuki
    Yabe, Yuichiro
    Kaneko, Atsushi
    Ito, Takayasu
    Oguchi, Takeshi
    Kida, Daihei
    Hirano, Yuji
    Fujibayashi, Takayoshi
    Sugiura, Fumiaki
    Hayashi, Masatoshi
    Funahashi, Koji
    Hanabayashi, Masahiro
    Asai, Shuji
    Ishiguro, Naoki
    Kojima, Toshihisa
    CLINICAL RHEUMATOLOGY, 2014, 33 (09) : 1247 - 1254
  • [46] Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept - Results from the nationwide Danish "Danbio" database
    Ostergaard, M
    Unkerskov, J
    Krogh, NS
    Friis, M
    Ravn, T
    Petri, A
    Andersen, LS
    Tarp, U
    Hansen, A
    Hetland, ML
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 59 - +
  • [47] Clinical significance of anti-cyclic citrullinated peptide (CCP) for the prediction of therapy outcome of patients with rheumatoid arthritis (RA) treated with etanercept
    Drynda, S.
    Wollenberg, H.
    Kekow, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 325 - 325
  • [48] Subclinical synovitis and tenosynovitis by ultrasonography (US) 7 score in patients with rheumatoid arthritis treated with synthetic drugs, in clinical remission by DAS28
    Ventura-Rios, Lucio
    Sanchez Bringas, Guadalupe
    Hernandez-Diaz, Cristina
    Cruz-Arenas, Esteban
    Burgos-Vargas, Ruben
    REUMATOLOGIA CLINICA, 2019, 15 (05): : E5 - E9
  • [49] Induction of Remission in Patients with up to 12 Months of Moderate-to-Severe Rheumatoid Arthritis Symptoms Treated with Etanercept Plus Methotrexate Over 52 Weeks
    Emery, Paul
    Hamoudeh, Mohammed
    FitzGerald, Oliver M.
    Combe, Bernard
    Gaylord, Stefanie
    Williams, Theresa
    Bukowski, Jack
    Pedersen, Ronald
    Koenig, Andrew S.
    Vlahos, Bonnie
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1077 - S1077
  • [50] Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement
    Bouman, C. A. M.
    van Herwaarden, N.
    van den Hoogen, F. H. J.
    van der Maas, A.
    van den Bemt, B. J. F.
    den Broeder, A. A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (06) : 597 - 603
12345